Hyperion DeFi, Inc.
HYPD - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$48.81M
Close$
$-2.94
191.3% downside
Current Fair Value
191.3% downsideOvervalued by 191.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $48.81 Million |
|---|---|
| Enterprise Value | $-676,489,055.00 |
| Earnings per Share | $-9.4 |
| Beta | 2.52 |
| Outstanding Shares | 14,173,457 |
Return
| Return on Equity | -37.39% |
|---|---|
| Return on Assets | -33.69% |
| Return on Invested Capital | -35.26% |
Valuation & Multiples
| P/E Ratio | -1.03 |
|---|---|
| PEG | 0.23 |
| Price to Sales | 0.06 |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | -0.83 |
| Enterprise Value to EBIT | 0.02 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -13.17 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$2.24
Consensus analyst estimateRevenue Estimate
$1.27 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$2.31
Consensus analyst estimateRevenue Estimate
$2.00 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.90%▼ 16.89% |
|---|---|
| Total Invested | $478,499▼ 93.96% |
| Investors Holding | 2▼ 31.00% |
About Eyenovia Inc
33 employees
CEO: Hyunsu Jung
Eyenovia, Inc. is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis.